Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GM-CSF-based cancer vaccines.

Glenn Dranoff1

  • 1Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. glenn_dranoff@dfci.harvard.edu

Immunological Reviews
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K <sup>+</sup> Supramolecular Attack Particles.

bioRxiv : the preprint server for biology·2026
Same author

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Cancer cell·2026
Same author

Plasticity of tumor cell immunogenicity: is it druggable?

Journal for immunotherapy of cancer·2025
Same author

First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma.

Cancer immunology research·2025
Same author

Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.

Cancer research communications·2024

Cancer vaccines engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) effectively stimulate immune responses against tumors. This approach shows promise in treating advanced melanoma by inducing antitumor immunity and causing metastasis necrosis.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Tumor immune recognition is crucial for cancer development.
  • Limited tumor immunogenicity hinders host suppression of cancer.
  • Cytokines in the tumor microenvironment significantly impact host immunity.

Purpose of the Study:

  • To identify molecules that enhance tumor immunity via gene transfer into cancer cells.
  • To evaluate the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunostimulatory agent.
  • To assess a novel cancer vaccination strategy in preclinical models and advanced melanoma patients.

Main Methods:

  • Gene transfer of various molecules into cancer cells for comparative analysis.
  • Utilizing multiple murine models to test tumor immunity augmentation.

Related Experiment Videos

  • Administering GM-CSF-secreting tumor cell vaccines to patients with advanced melanoma.
  • Assessing cellular and humoral antitumor responses and clinical outcomes.

    • Main Results:

    • Granulocyte-macrophage colony-stimulating factor (GM-CSF) was identified as the most potent immunostimulatory product.
    • GM-CSF secreting tumor cell vaccination enhanced antigen presentation by dendritic cells and macrophages.
    • Vaccination induced coordinated immune responses involving T cells, NKT cells, and antibodies, leading to protective immunity.
    • Clinical evaluation in advanced melanoma patients demonstrated consistent induction of antitumor responses and significant metastasis necrosis.

    Conclusions:

    • GM-CSF secreting tumor cell vaccination is a potent strategy for augmenting antitumor immunity.
    • This approach effectively overcomes limited tumor immunogenicity and promotes tumor regression.
    • Simplified manufacturing of autologous GM-CSF secreting tumor cells facilitates broader clinical application.
    • The findings support further clinical investigation of GM-CSF based cancer vaccines in various patient populations.